Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company…
News
Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company…
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
— Reimbursed early access program allows for patients with hypothalamic obesity in France to receive…
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
— Reimbursed early access program allows for patients with hypothalamic obesity in France to receive…
22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023
BUFFALO, N.Y., Aug. 07, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023
BUFFALO, N.Y., Aug. 07, 2023 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now available Added reporting customized…
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now available Added reporting customized…
Collegium Announces $50 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
Collegium Announces $50 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care,…
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care,…
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage…
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage…
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
— Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and…
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
— Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and…
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
— VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within…
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
— VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within…
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
– Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced;…
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
– Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced;…